Peptide-Based Gastrointestinal Disorders Therapeutics Market Segments With The Aid Of An Effective Customer Segmentation Strategy | Ironwood Pharmaceuticals, Inc

Overview:

Short strands of amino acid monomers united by peptide (amide) bonds are known as peptides. Peptide-based gastrointestinal (GIT) conditions therapeutics are medications utilized in different GIT condition therapies such as long-term constipation, concise bowel syndrome, and irritable bowel syndrome. Recently, several peptide-based therapeutics like Linaclotide, Teduglutide, and Trulance got authorization regarding the GIT condition therapy.

Get Sample Report With Latest Covid19 Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/2028

The guanylate cyclase-C agonist exhibited for chronic idiopathic constipation therapy in the adult population is known as Trulance. The 14 amino acid peptide whose function is as an agonist of guanylate cyclase C receptors in the intestinal region is known as Linaclotide. It is a partially soaked agonist of the intestinal guanylate cyclase C receptors and is utilized in incurable constipation and irritable bowel syndrome therapy. Teduglutide is a recently developed recombinant analogue for glucagon-like peptide (GLP) -2, an inherently stimulating peptide, which is perspired especially for the bottom gastrointestinal region.

Market Dynamics:

Routine authorization and releasing new peptide-based gastrointestinal conditions therapeutics in main regional markets had anticipated pushing the global peptide-based gastrointestinal disorders therapeutics market growth in the predicted time duration.

For instance, in 2012, the U.S. Food and Drug Administration authorized a medication known as Linzess (linaclotide) created in collaboration with Forest Laboratories, Inc. and Ironwood Pharmaceuticals, Inc. The Linzess (linaclotide) is a guanylate cyclase-C agonist utilized in chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) therapy.

In 2016, Ironwood Pharmaceuticals, Inc.’s collaboration with Astellas Pharma Inc. acquired trade authorization from the Japanese Ministry of Health, Labor, and Welfare for Linzess (linaclotide), and in 2017, Astellas Pharma Inc. launched Linzess (linaclotide) in Japan.

Request Here For PDF Brochure With Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/2028

Likewise, the growing majority of gastrointestinal conditions had anticipated the rising need for peptide-based medicines that will drive the development of the global peptide-based gastrointestinal disorders therapeutics market. For instance, based on the report published in 2016 by the International Foundation for Functional Gastrointestinal Disorder, the most common functional gastrointestinal (GI) disorder in the world is irritable bowel syndrome (IBS), which acquires almost 10% to 15% of the global population.

Regional Analysis:

The North American regional market for peptide-based gastrointestinal disorders therapeutics had anticipated exhibiting significant development in predicted time duration, due to the existence of giant companies and adopting other methods such as partnerships and mergers by them to new peptide-based therapeutics.

The Asia Pacific regional market had anticipated exhibiting a substantial boost in the predicted duration, due to growing acquisitions completed by regional companies for receiving permission for new peptide-based therapeutics. For instance, in 2014, a Japanese pharmaceutical firm Astellas Pharma Inc. funded Ironwood Pharmaceuticals, Inc. with an estimated US$ 15 million, to begin the stage III clinical testing for Linzess (linaclotide) in Japan. In 2016, it got authorization from the Japanese Ministry of Health, Labor, and Welfare.

Key Players:

Major companies working in the global peptide-based gastrointestinal disorders therapeutics market contain Allergan plc., Astellas Pharma Inc., Cipher Pharmaceuticals Inc., Ironwood Pharmaceuticals, Inc., NPS Pharmaceuticals, Inc., and Synergy Pharmaceuticals Inc.

Taxonomy:

The global peptide-based gastrointestinal disorders therapeutics market is divided based on drugs, application, route of administration, distribution channel, and geography.

By Drugs:

• Linaclotide

• Plecanatide (Trulance)

• Teduglutide

By Application:

• Chronic Constipation

• Irritable Bowel Syndrome

• Short Bowel Syndrome

• Others

By Route of Administration:

• Injectable

• Oral

By Distribution Channel:

• Hospital Pharmacies

• Online Pharmacies

• Retail Pharmacies

By Geography:

• North America

• Africa

• Asia Pacific

• Europe

• Latin America

• Middle East

Buy This Complete Business Report With Flat USD 2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/2028

Reasons to Purchase This Report

• Current and future of Peptide-Based Gastrointestinal Disorders Therapeutics Market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players

Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Peptide-Based Gastrointestinal Disorders Therapeutics Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Peptide-Based Gastrointestinal Disorders Therapeutics Industry Impact

Chapter 2 Global Peptide-Based Gastrointestinal Disorders Therapeutics Competition by Types, Applications, and Top Regions and Countries
2.1 Global Peptide-Based Gastrointestinal Disorders Therapeutics (Volume and Value) by Type
2.3 Global Peptide-Based Gastrointestinal Disorders Therapeutics (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Peptide-Based Gastrointestinal Disorders Therapeutics Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Peptide-Based Gastrointestinal Disorders Therapeutics Market Analysis
Chapter 6 East Asia Peptide-Based Gastrointestinal Disorders Therapeutics Market Analysis
Chapter 7 Europe Peptide-Based Gastrointestinal Disorders Therapeutics Market Analysis
Chapter 8 South Asia Peptide-Based Gastrointestinal Disorders Therapeutics Market Analysis
Chapter 9 Southeast Asia Peptide-Based Gastrointestinal Disorders Therapeutics Market Analysis
Chapter 10 Middle East Peptide-Based Gastrointestinal Disorders Therapeutics Market Analysis
Chapter 11 Africa Peptide-Based Gastrointestinal Disorders Therapeutics Market Analysis
Chapter 12 Oceania Peptide-Based Gastrointestinal Disorders Therapeutics Market Analysis
Chapter 13 South America Peptide-Based Gastrointestinal Disorders Therapeutics Market Analysis
Chapter 14 Company Profiles and Key Figures in Peptide-Based Gastrointestinal Disorders Therapeutics Business
Chapter 15 Global Peptide-Based Gastrointestinal Disorders Therapeutics Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology